What is Insitro?
Insitro operates at the vanguard of the digital biology revolution, utilizing a sophisticated machine learning engine to decode the complexities of human disease. By bridging the gap between in vitro cellular models and clinical outcomes, the company aims to reduce the time and cost associated with traditional pharmaceutical research. Its interdisciplinary team of data scientists, engineers, and life scientists is focused on identifying novel therapeutic targets that were previously obscured by the limitations of conventional research methodologies. This data-centric approach positions Insitro as a critical infrastructure player in the modern biopharmaceutical ecosystem.
How much funding has Insitro raised?
Insitro has raised a total of $643M across 3 funding rounds:
Series A
$100M
Series B
$143M
Series C
$400M
Series A (2019): $100M with participation from Third Rock Ventures, Mubadala, ARCH VENTURE PARTNERS, Verily, Foresite Capital, Bezos Expeditions, Two Sigma Ventures, and GV
Series B (2020): $143M led by WuXi AppTec, Andreessen Horowitz, BlackRock, T. Rowe Price Associates, HOF Capital, CPP Investments, and Casdin Capital
Series C (2021): $400M supported by T. Rowe Price Associates, BlackRock, Two Sigma Ventures, Andreessen Horowitz, HOF Capital, Casdin Capital, Alexandria Venture Investments, GV, Third Rock Ventures, Foresite Capital, CPP Investments, and ARCH VENTURE PARTNERS
Key Investors in Insitro
Andreessen Horowitz
A prominent venture capital firm that invests in bold entrepreneurs building the future through technology, with a strong focus on the intersection of software and biology.
BlackRock
A global investment management firm providing institutional-grade capital and risk management expertise to support large-scale, long-term growth initiatives.
T. Rowe Price Associates
A global asset management organization known for its active investment management and long-term perspective on high-growth, research-driven enterprises.
What's next for Insitro?
With the successful completion of its latest financing round, Insitro is well-positioned to scale its operational capacity and deepen its research capabilities. The company is expected to prioritize the advancement of its internal therapeutic programs while potentially exploring new strategic partnerships to validate its platform across diverse disease indications. As the firm transitions into a more mature phase of development, the focus will likely shift toward clinical validation and the systematic scaling of its data-generation engine, further cementing its role as a foundational entity in the future of precision medicine.
See full Insitro company page
